Glutamate suppresses osteoclastogenesis through the cystine/glutamate antiporter

Eiichi Hinoi, Takeshi Takarada, Kyosuke Uno, Maki Inoue, Yasuhiro Murafuji, Yukio Yoneda

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Previous studies have demonstrated functional expression of different glutamate receptor subtypes (GluRs) in both osteoblasts and osteoclasts. In the present study, we investigated the possible functional expression by osteoclasts of different glutamatergic signaling machineries including GluRs. In disagreement with the aforementioned prevailing view, no mRNA expression was found for all GluRs examined in primary cultured mouse osteoclasts differentiated from bone marrow precursors. Constitutive expression of mRNA was seen with glutamate transporters, such as excitatory amino acid transporters and cystine/glutamate antiporter, in primary osteoclasts. Glutamate significantly inhibited osteoclastogenesis at a concentration over 500 μmol/L in both primary osteoclasts and preosteoclastic RAW264.7 cells without affecting the cell viability in a manner sensitive to the antiporter inhibitor. In RAW264.7 cells stably overexpressing the cystine/glutamate antiporter, the inhibition by glutamate was more conspicuous than in cells transfected with empty vector alone. The systemic administration of glutamate significantly prevented the decreased bone mineral density in both femur and tibia in addition to increased osteoclastic indices in ovariectomized mice in vivo. These results suggest that glutamate may play a pivotal role in mechanisms associated with osteoclastogenesis through the cystine/glutamate antiporter functionally expressed by osteoclasts devoid of any GluRs cloned to date.

Original languageEnglish
Pages (from-to)1277-1290
Number of pages14
JournalAmerican Journal of Pathology
Volume170
Issue number4
DOIs
Publication statusPublished - Apr 2007
Externally publishedYes

Fingerprint

Antiporters
Cystine
Osteogenesis
Osteoclasts
Glutamic Acid
Amino Acid Transport Systems
Amino Acid Transport System X-AG
Messenger RNA
Excitatory Amino Acids
Glutamate Receptors
Osteoblasts
Tibia
Bone Density
Femur
Cell Survival
Bone Marrow

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Glutamate suppresses osteoclastogenesis through the cystine/glutamate antiporter. / Hinoi, Eiichi; Takarada, Takeshi; Uno, Kyosuke; Inoue, Maki; Murafuji, Yasuhiro; Yoneda, Yukio.

In: American Journal of Pathology, Vol. 170, No. 4, 04.2007, p. 1277-1290.

Research output: Contribution to journalArticle

Hinoi, Eiichi ; Takarada, Takeshi ; Uno, Kyosuke ; Inoue, Maki ; Murafuji, Yasuhiro ; Yoneda, Yukio. / Glutamate suppresses osteoclastogenesis through the cystine/glutamate antiporter. In: American Journal of Pathology. 2007 ; Vol. 170, No. 4. pp. 1277-1290.
@article{7e5f724fd6834092b0bc9776aa6b0e92,
title = "Glutamate suppresses osteoclastogenesis through the cystine/glutamate antiporter",
abstract = "Previous studies have demonstrated functional expression of different glutamate receptor subtypes (GluRs) in both osteoblasts and osteoclasts. In the present study, we investigated the possible functional expression by osteoclasts of different glutamatergic signaling machineries including GluRs. In disagreement with the aforementioned prevailing view, no mRNA expression was found for all GluRs examined in primary cultured mouse osteoclasts differentiated from bone marrow precursors. Constitutive expression of mRNA was seen with glutamate transporters, such as excitatory amino acid transporters and cystine/glutamate antiporter, in primary osteoclasts. Glutamate significantly inhibited osteoclastogenesis at a concentration over 500 μmol/L in both primary osteoclasts and preosteoclastic RAW264.7 cells without affecting the cell viability in a manner sensitive to the antiporter inhibitor. In RAW264.7 cells stably overexpressing the cystine/glutamate antiporter, the inhibition by glutamate was more conspicuous than in cells transfected with empty vector alone. The systemic administration of glutamate significantly prevented the decreased bone mineral density in both femur and tibia in addition to increased osteoclastic indices in ovariectomized mice in vivo. These results suggest that glutamate may play a pivotal role in mechanisms associated with osteoclastogenesis through the cystine/glutamate antiporter functionally expressed by osteoclasts devoid of any GluRs cloned to date.",
author = "Eiichi Hinoi and Takeshi Takarada and Kyosuke Uno and Maki Inoue and Yasuhiro Murafuji and Yukio Yoneda",
year = "2007",
month = "4",
doi = "10.2353/ajpath.2007.061039",
language = "English",
volume = "170",
pages = "1277--1290",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Glutamate suppresses osteoclastogenesis through the cystine/glutamate antiporter

AU - Hinoi, Eiichi

AU - Takarada, Takeshi

AU - Uno, Kyosuke

AU - Inoue, Maki

AU - Murafuji, Yasuhiro

AU - Yoneda, Yukio

PY - 2007/4

Y1 - 2007/4

N2 - Previous studies have demonstrated functional expression of different glutamate receptor subtypes (GluRs) in both osteoblasts and osteoclasts. In the present study, we investigated the possible functional expression by osteoclasts of different glutamatergic signaling machineries including GluRs. In disagreement with the aforementioned prevailing view, no mRNA expression was found for all GluRs examined in primary cultured mouse osteoclasts differentiated from bone marrow precursors. Constitutive expression of mRNA was seen with glutamate transporters, such as excitatory amino acid transporters and cystine/glutamate antiporter, in primary osteoclasts. Glutamate significantly inhibited osteoclastogenesis at a concentration over 500 μmol/L in both primary osteoclasts and preosteoclastic RAW264.7 cells without affecting the cell viability in a manner sensitive to the antiporter inhibitor. In RAW264.7 cells stably overexpressing the cystine/glutamate antiporter, the inhibition by glutamate was more conspicuous than in cells transfected with empty vector alone. The systemic administration of glutamate significantly prevented the decreased bone mineral density in both femur and tibia in addition to increased osteoclastic indices in ovariectomized mice in vivo. These results suggest that glutamate may play a pivotal role in mechanisms associated with osteoclastogenesis through the cystine/glutamate antiporter functionally expressed by osteoclasts devoid of any GluRs cloned to date.

AB - Previous studies have demonstrated functional expression of different glutamate receptor subtypes (GluRs) in both osteoblasts and osteoclasts. In the present study, we investigated the possible functional expression by osteoclasts of different glutamatergic signaling machineries including GluRs. In disagreement with the aforementioned prevailing view, no mRNA expression was found for all GluRs examined in primary cultured mouse osteoclasts differentiated from bone marrow precursors. Constitutive expression of mRNA was seen with glutamate transporters, such as excitatory amino acid transporters and cystine/glutamate antiporter, in primary osteoclasts. Glutamate significantly inhibited osteoclastogenesis at a concentration over 500 μmol/L in both primary osteoclasts and preosteoclastic RAW264.7 cells without affecting the cell viability in a manner sensitive to the antiporter inhibitor. In RAW264.7 cells stably overexpressing the cystine/glutamate antiporter, the inhibition by glutamate was more conspicuous than in cells transfected with empty vector alone. The systemic administration of glutamate significantly prevented the decreased bone mineral density in both femur and tibia in addition to increased osteoclastic indices in ovariectomized mice in vivo. These results suggest that glutamate may play a pivotal role in mechanisms associated with osteoclastogenesis through the cystine/glutamate antiporter functionally expressed by osteoclasts devoid of any GluRs cloned to date.

UR - http://www.scopus.com/inward/record.url?scp=34247866331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247866331&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2007.061039

DO - 10.2353/ajpath.2007.061039

M3 - Article

C2 - 17392167

AN - SCOPUS:34247866331

VL - 170

SP - 1277

EP - 1290

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -